StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
AMWL$7.97+0.00%
Fair $7.97+0.0%

AMWL

American Well Corporation

Healthcare / Health Information ServicesNYSE

$7.97

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $7.97Fund rank 27/100 · Data gapFallback financials|
SA 1/F
F-Score: 4/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-127.5M · quality 60.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

1/100

F

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 8Warnings: 2unknown: 8
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years ROE is -40.6%, below the 5% threshold
Thesis & Journal · AMWLLocal privado en este navegador · American Well Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$133M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-40.6%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2018–2025 · 7 años de histórico normalizado

Revenue CAGR

+11.8%

FCF CAGR

—

FCF margin

-26.5%

FCF / Net income

0.69x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $249.3M · net income $-95.7M · FCF $-66.0M

2018-FY → 2025-FY

Gross margin

—— pts

Operating margin

-42.2%+6.1% pts

Net margin

-38.4%+7.8% pts

FCF margin

-26.5%+40.2% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
Income Statement
Revenue$249.3M$249.3M$254.4M$259.0M$277.2M$252.8M$245.3M$148.9M$114.0M
Net Income$-95.7M$-95.7M$-208.1M$-675.2M$-270.4M$-176.3M$-224.4M$-87.2M$-52.7M
EBITDA$-71.3M$-71.3M$-184.6M$-660.6M$-249.7M$-163.1M$-217.3M$-86.9M$-49.8M
EPS-5.96-5.96-13.88-47.50-19.72-0.69-2.27——
Operating Margin-42.2%-42.2%-85.5%-267.2%-99.5%-70.9%-92.7%-63.6%-48.4%
Net Margin-38.4%-38.4%-81.8%-260.6%-97.6%-69.8%-91.5%-58.6%-46.2%
Cash Flow
Free Cash Flow$-66.0M$-66.0M$-127.5M$-148.5M$-192.6M$-142.1M$-115.8M$-83.2M$-75.9M
Returns
ROE-40.6%-40.6%-68.3%-145.4%-25.4%-14.2%-18.3%28.4%—
Growth & Yield
Revenue Growth-2.0%-2.0%-1.8%-6.5%9.7%3.1%64.8%30.6%—
EPS Growth57.1%57.1%70.8%-140.9%-2758.0%69.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.